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We determined the age- and location-specific sero-
prevalence of antibodies against 2009 pandemic influ-
enza A(H1N1) virus in Scotland following the first two 
waves of infection. Serum samples collected following 
the winter outbreak were analysed by microneutralisa-
tion assay. The proportion of positive sera varied sig-
nificantly between cities and, in the case of Inverness, 
between age groups (with younger adults more likely 
to be positive than older individuals). This study dem-
onstrates that older people are no longer more likely to 
have antibodies against the virus than younger adults.
The pandemic influenza A(H1N1) virus has been 
spreading throughout the world since May 2009. The 
objective of this study was to determine the age- and 
location-specific seroprevalence of antibodies against 
2009 pandemic influenza A(H1N1) virus in Scotland fol-
lowing the first two waves of the pandemic. Although 
population demographics and contact patterns will 
vary between countries, this information will assist 
European public health policy makers in planning for 
the 2010-11 influenza season. 
Methods
Anonymised sera from leftover diagnostic samples 
taken in March 2010 (subsequently referred to as hospi-
tal/general practice (GP) samples) were obtained from 
biochemistry laboratories in four cities in Scotland: 
Aberdeen, Edinburgh, Glasgow and Inverness. These 
biochemistry laboratories receive material from a 
range of hospital departments as well as from general 
practices. For each site, samples were categorised by 
age of patient (20-29, 30-39, 40-49 and over 50 years) 
and 100 samples of each age group at each site were 
sent to the West of Scotland Specialist Virology Centre 
for analysis. The sample size was chosen to have a 
power of at least 80% to detect a difference of 10% 
points in seroprevalence between two age groups or 
between two sites, based upon 400 observations in 
each site and in each age group. In addition, 100 ano-
nymised sera from leftover diagnostic samples taken 
in May 2010 in genito-urinary medicine (GUM) clinics 
in each of the four cities were collected (minimal influ-
enza activity occurred in Scotland between March 2010 
and May 2010 [1]), along with a further 128 routine hos-
pital/GP samples from patients in Glasgow aged over 
50. Antibody responses were detected by microneu-
tralisation assays, according to standard methods [2]. 
The virus strain used was the NYMC X-179A reassor-
tant derived from A/California/7/2009 (supplied by the 
National Institute for Biological Standards and Control, 
Potters Bar). Each serum sample was tested at a dilu-
tion of 1:40, since positivity at this dilution has pre-
viously been taken to indicate a significant antibody 
response [3]. Logistic regression analysis was used to 
estimate the effect of age group, location, and sample 
type on prevalence and 95% confidence intervals (CI) 
are used throughout. As a fixed sample size was used 
in each location, summary prevalences are based upon 
a weighted combination of the age and location spe-
cific prevalences for a stratified sample. The weights 
are derived from the population of Scotland in the age 
groups and catchment areas for the laboratories [4].
Results
Table 1 shows the percentage of hospital/GP samples 
that were found to be positive for antibodies against 
2009 pandemic influenza A(H1N1) virus by age and 
location. Among these samples there is strong evi-
dence from logistic regression modelling that the age 
seroprevalence profile is not the same at each site 
(p=0.0005). 
In Aberdeen, Edinburgh and Glasgow there do not 
appear to be significant intra-site variations in per-
centage positivity with age. However, in comparison 
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with Aberdeen and Edinburgh, there appears to be 
lower overall positivity in Glasgow, particularly among 
younger age groups. To confirm the results for Glasgow, 
we tested a further 128 hospital/GP samples from 
patients aged over 50 years and found 41 to be posi-
tive (32.0%; 95% CI: 23.9-40.1), compared with 33.0% 
(95% CI: 23.8–42.2) from the first batch of samples.
The samples obtained from general practices and 
hospital departments cannot be considered a ran-
dom sample from the general population as they are 
likely to have an overrepresentation among patients in 
groups more likely to receive an influenza vaccination. 
It is not likely that patients attending GUM clinics are 
over represented in such groups. The observation of 
similar levels of seroprevalence among 20-29 year-olds 
from GUM and hospital/GP samples at each of the four 
sites (p=0.19) is reassuring for the use of hospital/GP 
samples to estimate seroprevalence (Table 2).
Greater variation in percentage positivity was observed 
for Inverness, with a decrease in the percentage of 
positive samples with increased patient age. The geo-
graphical area served by the biochemistry laboratory 
in Inverness is larger, more rural, and considerably less 
densely populated than the catchment areas for the 
other biochemistry laboratories utilised in this study. A 
factor in the higher seroprevalence among 20-29 year-
olds compared to those over 50 years old from this 
area might be mobility: compared with older patients 
from the same site, 20-29 year-old patients from the 
Inverness area might be more likely to have travelled, 
Table 1
Hospital/general practice samples positive for antibodies against 2009 pandemic influenza A(H1N1) virus by age and 
location, Scotland, March 2010 (n=100 samples per age group in each location)
Location
Age group (years)





















Aberdeen 48% 38.2 - 57.8 51% 41.2 - 60.8 39% 29.4 - 48.6 39% 29.4 - 48.6
Edinburgh 40% 30.4 - 49.6 35% 25.7 - 44.3 28% 19.2 - 36.8 45% 35.2 - 54.8
Glasgow 22% 13.9 - 30.1 18% 10.5 - 25.5 26% 17.4 - 34.6 33% 23.8 - 42.2
Inverness 47% 37.2 - 56.8 29% 20.1 - 37.9 28% 19.2 - 36.8 19% 11.3 - 26.7
Table 2
Hospital/general practice and genito-urinary medicine clinical samples from patients aged 20-29 positive for antibodies 
against 2009 pandemic influenza A(H1N1) virus, Scotland, March 2010
Location
Hospital/GPa samplesb Genito-urinary medicinec
Percentage of positive samples 95% confidence interval Percentage of positive samples 95% confidence interval
Aberdeen 48.0% 38.2 - 57.8 45.5% 35.7 - 55.3
Edinburgh 40.0% 30.4 - 49.6 46.3% 36.3 - 56.3
Glasgow 22.0% 13.9 - 30.1 30.3% 21.1 - 39.4
Inverness 47.0% 37.2 - 56.8 53.0% 43.2 - 62.8
a GP: general practice.
b n=100 samples per location.
c n= 99 samples in Aberdeen; 95 samples in Edinburgh; 99 samples in Glasgow; 100 samples in Inverness.
Figure 
Age-adjusted estimates of seroprevalence by location and hospital admission rate per 100,000 population for the 
corresponding National Health Service board, Scotland, March 2010
Location
Estimated age-adjusted 
seroprevalence Hospital admission rate as a result of infection 
with 2009 pandemic influenza A(H1N1) per 100,000 
populationPercentage 95% confidence interval
Aberdeen 42.8% 38.1 - 47.6 40.3
Edinburgh 40.1% 33.5 - 46.7 35.5
Glasgow 27.7% 21.8 - 33.5 22.7
Inverness 28.8% 16.2 - 41.4 25.1
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acquired infection from other parts of Scotland, and 
mixed more with other individuals in their age group.
The Figure shows age-adjusted estimates of sero-
prevalence by location. When the age-adjustment is 
taken into account, there are higher overall levels of 
seroprevalence in Aberdeen and Edinburgh than in 
Glasgow and Inverness. These results appear to corre-
late with the rates of hospital admission as a result of 
infection with the virus (calculated from data contained 
within Health Protection Scotland’s Weekly Influenza 
Situation Reports [1]). Hospital admission rates as 
a result of infection with 2009 pandemic influenza 
A(H1N1) per 100,000 in Grampian (40.3) (the National 
Health Service board containing Aberdeen) and Lothian 
(35.5) (Edinburgh) were higher than those in Greater 
Glasgow and Clyde (22.7) (Glasgow) and Highland (25.1) 
(Inverness) (Figure). Health Protection Scotland have 
published influenza-like illness (ILI) and acute respira-
tory illness (ARI) consultation rates by National Health 
Service board [1], but these do not show major evi-
dence of regional variation. From the Health Protection 
Scotland Sentinel Surveillance Scheme (unpublished) 
there is some evidence that the 2009 pandemic influ-
enza A(H1N1) swab positivity rates in the East of 
Scotland (which includes Edinburgh) and the North of 
Scotland (Aberdeen and Inverness) are higher than in 
the West of Scotland (Glasgow).
Discussion
Since the outbreak of 2009 pandemic influenza 
A(H1N1) virus there have been several examinations 
of the frequency of antibodies against the virus [5 and 
references therein]. Taken together, these studies are 
contributing to our understanding of the spread of the 
virus and providing information that may help in plan-
ning future vaccination strategies. While hospital/GP 
samples cannot be considered to be a random sample 
from the general population, such samples have previ-
ously been used to estimate seroprevalence [3].
A goal of the work described here was to inform public 
health policy makers in planning for the 2010-11 influ-
enza season. It was felt that this would be done most 
effectively by making our results available as quickly 
as possible and as a result the only serum dilution that 
we have tested to date is 1:40. Microneutralisation 
assays at this dilution are in line with several other 
recent analyses of 2009 pandemic influenza A(H1N1) 
seroprevalence [5].
Recent studies in England, Finland, and Italy exam-
ined pre-pandemic serum samples and found that the 
proportions of samples which contained significant 
levels of antibodies that are protective against 2009 
pandemic influenza A(H1N1) virus increased with age 
[3,6,7]. During 2009, the burden of the virus was great-
est among people aged under 30 years [8]. It has been 
suggested that older adults were affected less because 
they were more likely to have previously been exposed 
to strains with similarities to the new virus.
In Scotland, following the two waves of infection that 
have occurred so far, it appears that older people are 
no longer more likely to have significant levels of anti-
bodies than young people. The seroprevalence among 
young people is, presumably, primarily due to expo-
sure during the two waves of infection. While we cur-
rently do not have seroprevalence data for individuals 
aged under 20 years, the results presented here would 
suggest that during the 2010-11 influenza season, the 
burden of infection among adults in Scotland might 
be similar across age groups, with levels of infection 
among young adults more in line with those seen in 
older age groups during 2009.
A weakness of this study is that we do not have any 
information on the risk group and vaccination status 
of the patients as only aggregate data, which did not 
link to any patient characteristics, could be used. This 
means we are unable to separate out the effect of vac-
cination from infection or to adjust seroprevalence 
among the hospital samples for possible selection bias 
associated with risk groups.
The results presented here will have implications 
for public health policy in Scotland. Planning for the 
2010-11 influenza season should include strategies to 
target risk groups as a significant proportion of the 
population remain susceptible to the virus. Glasgow 
and Inverness have lower overall levels of seropreva-
lence following the two waves of infection to date, and 
these cities might experience higher levels of influenza 
activity than Aberdeen or Edinburgh during the 2010-
11 influenza season. The case fatality rate for 2009 
pandemic influenza A(H1N1) among individuals aged 
over 65 years is greater than that observed for sea-
sonal influenza [9]. If the majority of people aged over 
50 years remain susceptible, targeting older individu-
als for vaccination should be a priority. This might be 
particularly desirable for the Inverness area, where our 
results indicate particularly high levels of susceptibil-
ity among older people.
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